Oncolytic virus (Adenoviral vector) · Kills target cells, directed at hyaluronic acid · developed by Theriva Biologics SL
Zabilugene almadenorepvec (VCN-01) is an oncolytic, replication-competent adenovirus encoding the human PH20 hyaluronidase. After intratumoral or intravenous administration it replicates in tumor cells, causing cell death and spreading to adjacent tumor cells, while the hyaluronidase degrades tumor hyaluronic acid. It is studied in pancreatic cancer and serous ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07701486 | Phase 1/2 | Pancreas Cancer, Metastatic | Recruiting | TOVX |
| NCT05057715 | Phase 1 | Pancreatic Cancer | Terminated | TOVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ductal Adenocarcinoma of the PancreasPancreas Cancer, MetastaticPancreas Cancer, Stage IVPancreatic CancerSerous Ovarian Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the TOVX page.
See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TOVX catalysts and pipeline →